Physician profile
Ronald Shade
NPI 1720049984
$25,059.59
in general payments reported to CMS, 2019-2025
69 companies · $7,045 in 2025
The $7,045 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,778 · 2020: $177 · 2021: $1,862 · 2022: $984 · 2023: $5,485 · 2024: $4,727 · 2025: $7,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,318 · Food and Beverage: $3,997 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,729 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,317.50 |
| Food and Beverage | $3,996.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,729.25 |
| Education | $213.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,878.09 | 2019-2024 | Imfinzi, Calquence, Enhertu |
| Avyxa Pharma, LLC | $3,307.88 | 2025 | |
| Astellas Pharma US INC | $2,581.83 | 2020-2025 | Vyloy, Padcev, Xospata |
| Beigene USA, INC. | $2,046.30 | 2021-2025 | Brukinsa, Tevimbra |
| Janssen Biotech, INC. | $1,801.76 | 2019-2025 | Tecvayli, Rybrevant, Talvey |
| Btg International INC. | $1,500.00 | 2024 | |
| Genentech USA, INC. | $1,491.67 | 2019-2025 | Tecentriq, Lunsumio, Columvi |
| Novartis Pharmaceuticals Corporation | $729.52 | 2019-2025 | Piqray, Kisqali |
| Abbvie INC. | $332.78 | 2019-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $321.90 | 2019-2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $291.04 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $271.94 | 2021-2025 | Trodelvy |
| Pfizer INC. | $242.01 | 2019-2025 | |
| Seagen INC. | $227.15 | 2021-2023 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $215.76 | 2019-2025 | Alunbrig, Ninlaro, Fruzaqla |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Shade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.